Table 5 Overview of optical coherence tomography (OCT) biomarkers over the course of the study. Statistical significance was calculated using the Chi-squared test
Overall (n = 57) | |||||
Baseline | Month 2 | Month 4 | Month 6 | p | |
DRIL, n (%) | |||||
No | 23 (40.4) | 25 (43.9) | 25 (48.1) | 27 (47.4) | 0.8365 |
Yes | 34 (59.6) | 32 (56.1) | 27 (51.9) | 30 (52.6) | |
HRF, n (%) | |||||
< 10 | 16 (28.1) | 32 (56.1) | 25 (48.1) | 24 (42.1) | 0.0851 |
10–20 | 23 (40.4) | 13 (22.8) | 12 (23.1) | 15 (26.3) | |
> 20 | 18 (31.6) | 12 (21.1) | 15 (28.8) | 18 (31.6) | |
Cyst, n (%) | |||||
No Cysts | 0 (0.0) | 31 (54.4) | 10 (19.2) | 20 (35.1) | < 0.0001 |
< 100 μm3 | 2 (3.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
100–200 μm3 | 12 (21.4) | 7 (12.3) | 4 (7.7) | 4 (7.0) | |
> 200 μm3 | 42 (75.0) | 19 (33.3) | 38 (73.1) | 33 (57.9) | |
ELM status, n (%) | |||||
Non-disrupted | 13 (22.8) | 10 (17.9) | 8 (15.4) | 15 (26.8) | 0.8122 |
Partially disrupted | 24 (42.1) | 28 (50.0) | 25 (48.1) | 24 (42.9) | |
Disrupted | 20 (35.1) | 18 (32.1) | 19 (36.5) | 17 (30.4) | |
CRVO (n = 15) | |||||
Baseline | Month 2 | Month 4 | Month 6 | p | |
DRIL, n (%) | |||||
No | 5 (33.3) | 2 (13.3) | 4 (30.8) | 4 (26.7) | 0.6078 |
Yes | 10 (66.7) | 13 (86.7) | 9 (69.2) | 11 (73.3) | |
HRF, n (%) | |||||
< 10 | 3 (20.0) | 9 (60.0) | 5 (38.5) | 9 (60.0) | 0.0028 |
10–20 | 11 (73.3) | 4 (26.7) | 2 (15.4) | 2 (13.3) | |
> 20 | 1 (6.7) | 2 (13.3) | 6 (46.29 | 4826.7) | |
Cyst, n (%) | |||||
No Cysts | 0 (0.0) | 9 (60.0) | 2 (15.4) | 5 (33.3) | 0.0016 |
< 100 μm3 | 1 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
100–200 μm3 | 5 (33.3) | 0 (0.0) | 0 (0.0) | 1 (6.7) | |
> 200 μm3 | 9 (60.0) | 6840.0) | 11 (84.6) | 9 (60.0) | |
ELM status, n (%) | |||||
Non-disrupted | 2 (13.3) | 3 (21.4) | 2 (15.4) | 3 (20.0) | 0.9950 |
Partially disrupted | 6 (40.0) | 5 (35.7) | 6 (46.2) | 6 (40.0) | |
Disrupted | 7 (46.7) | 6 (42.9) | 5 (38.5) | 6 (40.0) | |
BRVO (n = 42) | |||||
Baseline | Month 2 | Month 4 | Month 6 | p | |
DRIL, n (%) | |||||
No | 18 (42.9) | 23 (54.8) | 21 (53.8) | 23 (54.8) | 0.6370 |
Yes | 24 (57.1) | 19 (45.2) | 18 (46.2) | 19 (45.2) | |
HRF, n (%) | |||||
< 10 | 13 (31.0) | 23 (54.8) | 20 (51.3) | 15 (35.7) | 0.2755 |
10–20 | 12 (28.6) | 9 (21.4) | 10 (25.6) | 13,831.0) | |
> 20 | 17 (40.5) | 10 (23.8) | 9 (23.1) | 14 (33.3) | |
Cyst, n (%) | |||||
No Cysts | 0 (0.0) | 22 (52.4) | 8 (20.5) | 15 (35.7) | < 0.0001 |
< 100 μm3 | 1 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
100–200 μm3 | 7 (17.1) | 7 (16.7) | 4 (10.3) | 3 (7.1) | |
> 200 μm3 | 33 (80.5) | 13 (31.0) | 27 (69.2) | 24 (57.1) | |
ELM status, n (%) | |||||
Non-disrupted | 11 (26.2) | 7 (16.7) | 6 (15.4) | 12 (29.3) | 0.6724 |
Partially disrupted | 18 (42.9) | 23 (54.8) | 19 (48.7) | 18 (43.9) | |
Disrupted | 13 (31.0) | 12 (28.6) | 14 (35.9) | 11 (26.8) | |